Option Care Stock Trades Below McKesson's Deal Price — Here's the Spread - Option Care Health (NASDAQ:OPC

Option Care Health (OPCH) agreed to be taken private by Clayton Dubilier & Rice and McKesson (MCK) for $32.05 per share, valuing the company at $5.8B. Shares traded at $31.05, leaving a $1.00 spread. The deal is expected to close in H1 2027, subject to approvals. McKesson will invest $1.4B for a 49% stake, with an option to buy out CD&R later. OPCH shares rose 32.78% on the news.

Original reporting
Published Oct 6, 2026, 7:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 8:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$OPCH
Neutral
high confidence
Mentioned
$OPCH · $MCK
Relevance
9/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$OPCHNeutralMed
01

Why it matters

The deal creates a $1 per share arbitrage spread, translating to a 3.2% gross return, with an annualized 4.4% if the transaction closes at the end of the first half of 2027.

02

Market read

The announcement provides a fresh arbitrage opportunity in the healthcare sector, with a clear price target and defined timeline.

03

What to watch

Potential regulatory or state‑healthcare approvals could delay or derail the transaction, adding risk to the arbitrage play.

Relevance 9/10Novelty 9/10Timing: today

Background

Option Care Health, a home‑infusion provider, announced a take‑private deal with private‑equity firm Clayton Dubilier & Rice and distributor McKesson.

Company-level read

Ticker impact

$OPCHNeutralHigh confidence
Context

Option Care Health agreed to be taken private at $32.05 per share, creating an arbitrage spread versus current market price.

Expected impact

likely upward pressure as arbitrage traders push the price toward $32.05, but limited upside due to thin spread and long timeline.

Evidence & confidence

Deal is newly disclosed, sizable ($5.8 B), and the spread is explicitly quantified, giving traders a clear target.

$MCKNeutralMedium confidence
Context

McKesson is a co‑buyer in the $32.05 per share take‑private transaction for Option Care Health.

Expected impact

minimal direct impact; any movement will mirror the arbitrage dynamics of OPCH rather than McKesson’s own fundamentals.

Evidence & confidence

While McKesson is a party, the market focus is on the target; the buyer’s stock typically sees limited reaction.

Market effects

The home‑infusion sector may see heightened M&A interest as consolidation accelerates.

U.S. healthcare M&A activity could receive a modest boost, but broader market impact is limited.

Limited to investors tracking U.S. healthcare deals and arbitrage strategies.

Counterpoint

The thin spread and long closing timeline may deter arbitrageurs, leading to a stagnant price rather than a rally.

Key entities

  • Option Care Health

    Target of the $32.05 per share buyout.

  • Clayton Dubilier & Rice

    Co‑buyer acquiring 51% of Option Care.

  • McKesson Corp.

    Co‑buyer acquiring 49% of Option Care.

Related articles

$MCKHighAI 8/10

Healthcare providers & services stocks Q3 results: Benchmarking McKesson

McKesson (MCK) reported Q3 revenue of $111B, up 7.6% YoY, beating estimates. LifeStance Health (LFST) saw 25.3% revenue growth, while Brookdale (BKD) reported a 12.4% decline. Elevance Health (ELV) and The Pennant Group (PNTG) also released Q3 results, with mixed outcomes. Sector revenues beat estimates by 2.2%, and stocks are up 4.4% on average since earnings.

$MCKMedAI 8/10

Sales of Pharmaceuticals, GLP-1s Send McKesson Shares to New Highs

McKesson (MCK), the largest U.S. pharmaceutical distributor, reported Q2 2027 revenue of $111B (up 8% YoY), driven by North American pharmaceuticals and GLP-1 distribution. Operating profit rose 13% to $1.9B, and adjusted EPS increased 18% to $11.68. The company raised full-year EPS guidance to up to $46.40, implying 19% growth. MCK shares are up 32% YTD, with strong institutional support and long-term growth trends.